143.77 +0.03 (0.02%)
After hours: 4:27PM EST
|Bid||143.67 x 1200|
|Ask||143.69 x 1400|
|Day's range||143.11 - 144.69|
|52-week range||104.90 - 164.13|
|Beta (3Y monthly)||0.88|
|PE ratio (TTM)||119.68|
|Earnings date||12 Feb 2020 - 17 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||176.06|
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
IQVIA (IQV) delivered earnings and revenue surprises of 1.91% and 0.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA's (IQV) latest launch is aimed at helping MedTech companies comply with the new European Union Medical Device Regulation, through extended capabilities.
IQVIA Holdings (IQV) is likely to benefit from the evolving growth opportunities in the life sciences industry. A highly leveraged balance sheet remains a concern.
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
IQVIA (IQV) delivered earnings and revenue surprises of 2.68% and 1.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Equifax (EFX) second-quarter 2019 revenues are likely to reflect weakness in the USIS, International and Global Consumer Solutions segments.